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Introduction
Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived stromal vascular fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I openlabel clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived stromal vascular fraction. Six and 12 month data have been reported. As patients were followed in our medical centre, we report their longer term outcome beyond the end of the trial.
Patients and method
Twelve females, mean age 54.5±10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30 months after treatment.
Results
Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted.
Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion.
Conclusion
Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived stromal vascular fraction injection. Two randomized double blind, placebocontrolled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.
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Introduction
Hand involvement is frequent in Systemic sclerosis (SSc) and confers a substantial handicap in work and daily activities [1] . To date, clinical care for the hand relies on vasodilators, cold and trauma protection, and regular physiotherapy. No antifibrotic therapy has proven effective.
The regenerative properties of cells derived from adipose tissue have been explored for over a decade. In 2002, Zuk identified and described a putative population of multipotent stem and progenitor cells within the stromal vascular fraction (SVF) cell population derived by enzymatic digestion of adipose tissue [2] . The SVF is composed of blood cells, fibroblasts, endothelial cells and their progenitors, pericytes, adipose stromal/stem cells (ASC) and preadipocytes. This population has been reported to possess multiple angiogenic, antiinflammatory, immunomodulatory and regenerative properties [3] .
We previously performed a phase I open-label single center clinical trial, called SCLERADEC (NTC01813279) assessing the safety and efficacy of adipose-derived stromal vascular fraction (ADSVF) in 12 SSc patients followed for 6 months [4] , and later reported their extending outcome at 12 months [5] . We took advantage of routine medical follow-up of these patients to assess their longer term outcome. 
Patients and methods
Patients
Results
Consistent with prior reports [4, 5] , no evidence of treatment-related adverse events was noted in any patient. Results of functional assessments are shown in Table 1 and Figure 1 . Results show that the benefit reported at the 6 month time point of the trial is sustained at 22-30 months. For example, the long-term follow-up data for CHFS, SHAQ, and RCS endpoints showed 62.5%, 51.1% and 88.3% improvement over baseline respectively. It is worth noting that the decrease of the VAS for hand pain which had lost statistical significance at 12 months post-surgery [5] regained significance at 24 months (33.1% decrease from baseline) ( Figure 1 ). Improvement in objective endpoints such as Jamar grip strength reported at 6 months was sustained in the current assessment while pinch strength showed continued improvement. The 
Discussion
While the current report is limited by the repetition of hand assessment in an extended followup from an original phase I open label study and the potential bias related to natural course of the disease and the seasonal effect, the long-term assessment is in favour of safety and durability of the effect. Given the costs associated with preparation of an autologous autologous cell therapy product to standards required by local, national, and European regulatory authorities it is important to assess the apparent durability of the response in order to begin to build a pharmaco-economic argument for or against this therapy. The current study, with evidence of apparently sustained-possibly progressive-improvement and the reduction in need for costly medications such as iloprost, represents the first step in building the data set needed for a cost-benefit assessment. Due to the lack of a placebo group, we are aware that we cannot be definitive about the causal link between the long-term hand improvement and ADSVF injection. However, it appears somewhat unlikely that the substantial magnitude of change over such a prolonged period could be attributed to a placebo effect and is unlikely to represent spontaneous sustained positive changes in the natural history of the disease. Rather, from a physiopathological point of view, we believe that the combined and synergistic pro-angiogenic, anti-inflammatory, anti-fibrotic and immunomodulatory effects possessed by the ASC and other progenitor cells inside the ADSVF [3] could explain these clinical results. Of course, the final determination of this question will depend upon the results of the robust randomized, placebo-controlled trials such as the two trials currently underway in France and in the USA.
Conclusion
Although interpretation of these results is hampered by the lack of a control group, the use of autologous ADSVF is an innovative therapy which appears to provide benefit for patients 
